DelveInsight’s, “Cerebral Infarction – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cerebral Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Cerebral Infarction Understanding
Cerebral Infarction: Overview
Infarction refers to death of tissue. A cerebral infarction also known as ischemic stroke, or stroke, is a brain lesion in which a cluster of brain cells die when they don't get enough blood. A lack of adequate blood supply to brain cells deprives them of oxygen and vital nutrients which can cause parts of the brain to die off. The reduced blood supply to the brain is caused by atherosclerosis which gives rise to the formation of a fatty plaque in the blood vessel called an atheroma. Symptoms and signs of a stroke: difficulty speaking, difficulty understanding or confusion, especially with simple tasks, difficulty with muscle strength, especially on one side of the body, severe headache and vision changes.

"Cerebral Infarction - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cerebral Infarction pipeline landscape is provided which includes the disease overview and Cerebral Infarction treatment guidelines. The assessment part of the report embraces, in depth Cerebral Infarction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cerebral Infarction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
● The companies and academics are working to assess challenges and seek opportunities that could influence Cerebral Infarction R&D. The therapies under development are focused on novel approaches to treat/improve Cerebral Infarction.

Cerebral Infarction Emerging Drugs Chapters
This segment of the Cerebral Infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cerebral Infarction Emerging Drugs
● PMZ-1620: Pharamzz
Sovateltide (IRL-1620, PMZ-1620), an endothelin-B receptor agonist, has been shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered intravenously. The drug is being studied in phase III stage for the treatment of pateints with cerebral infarction/ Cerebral Ischemic stroke.

● BAY 2433334: Bayer
BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor. The drug is in phase II clinical trials for Ischemic stroke.

● SP-8203: Shin Poong Pharmaceutical Co. Ltd.
SP-8203, under development in phase II, is a new neuroprotective compound for acute ischemic stroke. It is a quinazoline-2, 4-dione derivative with multiple potent neuroprotective mechanisms of action including anti-inflammatory activities.

● JTR-161: Teijin Pharma Limited
JTR-161 is a stem cell replacement therapy under development in phase I/II phase for the treatment of patients with Cerebral Infarction.
Further product details are provided in the report……..

Cerebral Infarction: Therapeutic Assessment
This segment of the report provides insights about the different Cerebral Infarction drugs segregated based on following parameters that define the scope of the report, such as:
● Major Players in Cerebral Infarction
There are approx. 20+ key companies which are developing the therapies for Cerebral Infarction. The companies which have their Cerebral Infarction drug candidates in the most advanced stage, i.e. phase III include, Pharmazz.
● Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration
Cerebral Infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

● Molecule Type
Products have been categorized under various Molecule types such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
● Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cerebral Infarction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cerebral Infarction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cerebral Infarction drugs.

Cerebral Infarction Report Insights
• Cerebral Infarction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cerebral Infarction Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cerebral Infarction drugs?
• How many Cerebral Infarction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cerebral Infarction?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cerebral Infarction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cerebral Infarction and their status?
• What are the key designations that have been granted to the emerging drugs?